Our mission is to alter the course of clinical disability experienced by patients with neurodegenerative diseases. We are pursuing this mission through our development of small molecules designed to reactivate innate repair pathways in order to restore function. In neurodegenerative diseases, neurons, axons, and their neural connections, or synapses, can lose function over time, leading to significant clinical disability. In order to impact the course of neurodegenerative diseases, we are focused on three key areas of precision neuroregeneration: (1) myelin restoration, or remyelination, (2) synaptic reconnection, and (3) axonal repair. Our approach focuses on small molecule targeting of select molecular pathways that we believe will lead to demonstrable improvements in clinical endpoints and disease modifying outcomes.